Patent ID: 7160899

Claim:
A method of treatment or alleviation of Parkinson's disease in a subject, which method comprises administering to said subject a combination of at least one compound having a neurotrophic activity which mimics or enhances the function of NGF, BDNF, and/or GDNF and at least one compound having adenosine A 2A receptor antagonist activity, wherein the compound having a neurotrophic activity is at least one compound selected from the group consisting of: 5-(4-Chlorophenyl)-8-methyl-6,7,8,9-tetrahydro-1-H-pyrrolo[3.2-h]isoquinoline-2,3-dione-3-oxime; 5-(4-Chlorophenyl)-6,7,8,9-tetrahydro-1-H-pyrrolo[3.2-h]naphthalene-2,3-dione-3-oxime; GDNF; and neublastin; and pharmaceutically acceptable salts thereof; and the compound having adenosine A 2A receptor antagonist activity is at least one compound selected from the group consisting of: KW-6002; ZM-241385; 8FB-PTP; SCH-58261; KF-17837; CGS-15943; DMPX; and pharmaceutically acceptable salts thereof, and wherein the combination of compounds administered is effective for treating or alleviating Parkinson's disease.